Clinical Trials Directory

We are doing this study to find out if adding drugs that target HER2 proteins to the standard therapy for endometrial cancer can improve the chance of remission or lower the risk that the cancer comes back after treatment. We want to know how well patients do on the standard treatment compared to two experimental study regimens.

We are doing this study to find the most effective, safe dose of an experimental drug called NX-5948 (the study drug). We want to know how well this study drug works in people with B-cell lymphomas.

We are doing this study to find out which type of surgery has the best outcomes for people who have shoulder dislocations with bone loss. There are 3 types of surgeries that doctors can perform to stabilize the shoulder of people who have this type of injury, but there is no evidence at this time that proves one is better than the others. We hope this study can help us figure out how to choose the best option for different patients. This is an observational study and participation will not affect the treatment option you choose to pursue.

We are doing this study to find out if an investigational drug called tozorakimab (the study drug) will work and be safe for treating COPD patients who have a history of COPD exacerbations (also called flare-ups, which is when your COPD gets worse).

We are doing this study to find out if an experimental gene transfer drug called OCU410 (the study drug) is a safe and effective option for geographic atrophy secondary to dry age-related macular degeneration.

We are doing this study to find out if an experimental gene transfer drug called OCU410ST is a safe and effective option for Stargardt Disease (STGD).

We are doing this study to learn more about the olfactory receptor expression (which give us our sense of smell) and neurogenesis (creation of cells) in human olfactory tissue.

We are doing this study to improve how cancer patients and their providers communicate with each other. We want to know how personal biases can affect how cancer care is explained and managed. We think being able to identify bias if any exists can improve care and patients' psychological well-being.